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The primary aim of this review was to evaluate the state of knowledge of
the geographical distribution of all infectious diseases of clinical significance
to humans. A systematic review was conducted to enumerate cartographic
progress, with respect to the data available for mapping and the methods
currently applied. The results helped define the minimum information
requirements for mapping infectious disease occurrence, and a quantitative
framework forassessing the mapping opportunities forall infectious diseases.
This revealed that of355infectious diseasesidentified,174(49%)have astrong
rationale for mapping and of these only 7 (4%) had been comprehensively
mapped. A variety of ambitions, such as the quantification of the global
burden of infectious disease, international biosurveillance, assessing the like-
lihood of infectious disease outbreaks and exploring the propensity for
infectious disease evolution and emergence, are limited by these omissions.
An overview of the factors hindering progress in disease cartography is pro-
vided. It is argued that rapid improvement in the landscape of infectious
diseases mapping can be made by embracing non-conventional data sources,
automation of geo-positioning and mapping procedures enabled by machine
learning and information technology, respectively, in addition to harnessing
labour of the volunteer ‘cognitive surplus’ through crowdsourcing.
1. Introduction
The primary goal of this review is to establish the minimum set of information
that is needed on the epidemiology of an infectious disease, to make an
informed decision on the most appropriate techniques for mapping its global
distribution. The assessment is intended to be applicable to all infectious dis-
eases of clinical significance in humans, but makes no attempt to prioritize
the case for mapping among the diseases considered.
More than 1400 species of infectious agents have been reported to cause
disease in humans [1–3]. These include pathogens for some 347 diseases of sus-
tained clinical importance, for which it is commercially viable to compile
information relevant to their diagnosis, epidemiology and therapy, as a
decision-support tool for clinicians [4,5]. Logistical constraints required a
focus in this review on these clinically important diseases. Among these there
are 110 diseases that pose a threat to non-immune travellers [4]. Sixty-two of
these clinically significant diseases can be prevented by vaccination; 19 usually
as routine childhood immunizations [4,6,7].
There are a variety of reasons for wanting to map the geographical distri-
bution of an infectious disease. Mapping is a primary goal in spatial
epidemiology [8–16]. Maps of disease distribution and intensity allow an
immediate visualization of the extent and magnitude of the public health
& 2013 The Authors. Published by the Royal Society under the terms of the Creative Commons Attribution
License http://creativecommons.org/licenses/by/3.0/, which permits unrestricted use, provided the original
author and source are credited.problem. When based on empirical evidence, maps can sup-
port carefully weighted assessments by decision makers on
the advantages and disadvantages of alternative courses of
action [17–19]. These may range from helping plan national
scale intervention strategies [20,21] to advice for individuals
on whether to vaccinate and/or provide prophylaxis before
travel [6,22]. These maps can also document a baseline
from which intervention success or failure can be monitored.
In addition, as modes of data gathering evolve and
improve (for example, through enhanced electronic surveil-
lance [17] and Internet-based health reporting [23],
including HealthMap/ProMED [24,25], BioCaster [26,27]
and Argus [28,29]) and techniques develop to exploit these
data (for example, semi-automated rapid mapping), these
geographical distributions (often referred to in this literature
as baseline disease risk assessments) can also provide a
‘normal’ against which real-time outbreak alerts can be
assessed for international biosurveillance [30–32].
Furthermore, as the portfolio of infectious disease distri-
bution maps expands and their fidelity improves, the
public health community will be better able to evaluate the
factors that predispose a time and place to the origin
[33,34], and emergence of infectious disease outbreaks
[3,35–42]. Unfortunately, contemporary inferences about
the fundamental ecology of infectious diseases (such as
decreased species richness [43] and increased range size
[44] with latitude and their potential for spread [45,46]) are
crude spatially because they rely on data not systematically
collected for this purpose and aggregated to the national
level [4]. Ultimately, this improved basic understanding
will help mitigate the processes that drive the diversity of
infectious disease threats with which we contend [47].
There is, therefore, a clear need to perform baseline risk
assessments for routine public health, improve biosurveillance
and provide better long-term preparedness by improving
fundamental epidemiological understanding [31].
An understanding of the public health benefit of the
mapping of infectious disease is not new [48–50] and selected
oldexamples for malariainclude thesereferences[51–55]. His-
torical disease cartography usually suffered at least one of the
following problems. First, authors very rarely documented
the evidence-base that was used to make the map. Second,
when mapping was implemented before the advent of geo-
graphical information systems, significant errors arose simply
as afunction of cartographic skill. These errors were magnified
enormously when working at global scales. Third, no assess-
ment of the fidelity of the map or how this precision might
vary spatially across the map extent was ever given. These
limitations constrained significantly the public health utility
of the maps and are to a greater or lesser extent resolved in
many of the contemporary mapping efforts reviewed here.
Today, there are a range of different geographical distri-
butions or baseline ‘risk’ maps available [56], which have
been derived for a variety of purposes, by a wide community
of public health cartographers using a diverse toolbox of map-
ping methods [8–16]. Moreover, the maps use a variety of
disease-related metrics (occurrence, incidence, prevalence),
andan even widerarrayof covariatesto informthe predictions
[8,57,58]. This complexity means that global comparisons
between maps of different diseases are extremely difficult
and wider synthesis remains elusive. In part, this review
aims to help audit and navigate this diversity and the sup-
plemental information provides an extensive bibliography
arising from a systematic review of all diseases of clinical
significance [4].
In this review, we also consider the minimum information
requirements for disease mapping. When considering carto-
graphic options for diseases of clinical importance, the first
question is: do we know the life cycle of the pathogen, its vec-
tors, reservoirs, hosts and routes of transmission? This
sounds trivial, but for many pathogens there is still consider-
able uncertainty around the life history. Second, do we have
information about the spatial and temporal patterns of the
disease? Third, do we understand the dynamic processes of
transmission that determine the patterns we observe in
space and time? This level of detail will usually indicate
some intimate epidemiological knowledge of covariates
(temperature, rainfall, land use patterns, etc.), that can help
in understanding the spatial and temporal distribution of a
disease. Progression along this gradient of questions reflects
increased basic epidemiological understanding and, there-
fore, an increased ability to map the disease. Fourth, it is
important to know what quantity and quality of data are
available for mapping. It is self-evident that more high qual-
ity contemporary data leads to more robust maps. Many
obstacles exist that can make the relevant data scarce, how-
ever. For example, health-related data may be closely
protected by governments and other institutions or these
data may simply be scattered so widely in the formal litera-
ture that their systematic assembly is a significant logistical
challenge. Fifth, it is also important to know whether pre-
vious credible mapping efforts have been conducted. This
will help answer questions one through four and, broadly
speaking, the longer the history of robust mapping activities,
the increased likelihood of reliable mapping outcomes.
The ability to map a disease stems largely from the type
of data that are available for mapping [10,15]. The accuracy
of maps is then largely determined by the abundance, spatial
representativeness and heterogeneity of those data [59]. Point
data types used in disease mapping are generally geo-
referenced occurrence or prevalence records. Occurrence
data simply record an observation of a disease at a given
location and time, and are characteristic of the data provided
routinely by HealthMap/ProMED [24,25], BioCaster [26,27]
and Argus [28,29]. The other commonly recorded point
data are infection prevalence surveys, which not only locate
a disease in time and space, but also measure the infected
fraction of the sampled local population and thus, enable
the standard quantification of the ‘abundance’ of a disease.
This is often referred to as its endemicity [60]. An accurate
global representation of the contemporary endemicity of a
disease is a key achievement for infectious disease mapping,
because it affords a rich diversity of operationally important
public health inferences: for example, clinical burden [61,62]
and basic reproductive number estimation [18,63] to inform
national elimination feasibility assessment [20,64].
A wide range of approaches have been developed for
empirical modelling of species and disease distributions,
given data on point observations of occurrence [65], with
the objective of identifying the fundamental niche of the
target organism [66,67]. Of the plethora available, the boosted
regression trees (BRT) method [68,69] is selected by the
authors as a default for occurrence mapping. A schematic
overview of the occurrence mapping process is provided in
figure 1. This selection was based on a number of factors:
first, in a review of 16 species modelling methods, BRT was
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2one of the top performing methods evaluated using the area
under the receiver operating characteristic curve (AUC) and
correlation statistics [16,70]; second, the method is flexible
in being able to accommodate different types of predictor
variables (e.g. continuous or categorical data); third, it is
easy to understand, implement and uses reliable, well docu-
mented and freely available R code [71]; and fourth, the
resulting maps are simple to interpret and include a ranked
list of environmental predictors. The authors also have exten-
sive experience with this technique after a global scale project
to map the distribution of the anophelines of public health
importance [72–76]. These references provide a detailed stat-
istical explanation and examples of how BRT was applied to
species distribution mapping.
Model-based geostatistics (MBG) [77,78] has recently
been more widely applied in infectious disease mapping
[17,79–83] and is the technique of choice where data allow.
There are several reasons for this. First, MBG deals explicitly
with the spatial (and with extension temporal) autocorrelation
of disease data; this is still widely ignored in occurrence
mapping. Second, MBG models can be configured to offer a
much more robust parameterization of factors that can affect
disease endemicity (such as age of the individuals sampled,
the diagnostic technique used, the influence of covariates
etc.). Third, by fitting the models using Bayesian inference,
outputs can be presented to show the full uncertainty of
the prediction in all parts of the predicted maps. The main
impediments to its wider use are the lack of bespoke software
with which to implement the models and its relatively large
computational burden.
We assume that advances with respect to occurrence
mapping or MBG techniques may modify our guidance
with regard to mapping techniques and elaborate on some
of the generic improvements that may be made in infectious
disease mapping in §4. Those we have favoured here are
proved methods that can be applied now.
In summary, the objective of this review is to formalize
the questions outlined in §1, in order to define rules for
advocating specific cartographic techniques for a baseline
risk assessment for each disease of clinical importance, and
then to assess to what level this mapping potential has
been realized. A substantial literature review has been
conducted to collate the data required to make those carto-
graphic suggestions evidence-based and is provided as
electronic supplementary material.
2. Material and methods
(a) Selection of infectious diseases of
clinical importance
A total of 347 infectious diseases of clinical importance were
selected for review based on the GIDEON database, accessed
November 2010. GIDEON is an infectious disease information
and diagnostic resource available online through subscription
that derives its content from a range of sources including formal
peer-reviewed journals and informal sources such as Ministry of
Health reports [4,5]. This list was then revised to 355 diseases
based on further re-definitions and decoupling of some groups.
These diseases were placed into one of 11 classifications based on
transmission type: animal contact, blood/body fluid contact,
direct contact, endogenous, food/water-borne, respiratory, sexual
contact, soil contact, unknown, vector-borne and water contact.
Revisions were as follows: mucosal and cutaneous leishma-
niasis were re-classified as cutaneous/mucosal leishmaniasis,
Old World and New World; the spotted fevers were also divided
into New and Old World to better differentiate between the var-
ious species of bacteria and ticks that spread the disease in
different parts of the world; malaria was split into Plasmodium
(a)
(c)
(b)
(d)
(e)
Figure 1. A schematic overview of a niche/occurrence mapping process (for example boosted regression trees (BRT)) that uses pseudo-absence data guided by
expert opinion. Consensus based definitive extent layers of infectious disease occurrence at the national level (a) are combined with accurately geo-positioned
occurrence (presence) locations (b) to generate pseudo-absence data (c). The presence (b) and pseudo-absence data (c) are then used in the BRT analyses, alongside
a suite of environmental covariates (d) to predict the probability of occurrence of the target disease (e).
r
s
t
b
.
r
o
y
a
l
s
o
c
i
e
t
y
p
u
b
l
i
s
h
i
n
g
.
o
r
g
P
h
i
l
T
r
a
n
s
R
S
o
c
B
3
6
8
:
2
0
1
2
0
2
5
0
3falciparum, Plasmodium vivax, Plasmodium ovale and Plasmodium
malariae, because variation in geographical range and epidemio-
logical patterns of these pathogenic species would be masked if
considered together; AIDS was removed and was combined
with HIV; conjunctivitis-inclusion was similarly removed, and
incorporated into trachoma; the umbrella term ‘adenovirus
infection’ was divided into acute febrile respiratory disease
(adenoviral), adenoviral haemorrhagic conjunctivitis, keratocon-
junctivitis (adenoviral) and adenovirus infection; similarly,
enterovirus infection was divided into enterovirus haemorrhagic
conjunctivitis and enterovirus infection; human herpesvirus 6
was renamed Roseola; sandfly fever was added because of its
possible impact on travellers; and avian influenza virus serotype
H5N1 was added because of its epidemic potential.
(b) Data assembly
(i) Natural history
Data were collected on the natural history of each infectious
agent. Information on the genus and species, disease reservoir,
vector species (if applicable), mode of transmission, incubation
period, vaccine (where relevant) and geographical distribution
was obtained using GIDEON. Taxonomic classifications were
supplemented by the Tree of Life Project (http://tolweb.org).
Further evidence regarding geographical distribution and vac-
cine development was found in the American Public Health
Association’s Control of Communicable Disease Manual [7].
(ii) Transmission dynamics
The basic reproduction number (R0) was used to quantify the
transmission potential of the various aetiological agents. The
R0 is defined as the average number of secondary infections pro-
duced when a single-infected individual is introduced into a
fully susceptible population [84–87]. A literature search was con-
ducted to obtain R0 values in humans and reservoirs of zoonotic
diseases. The search was carried out in PubMed (http://www.
pubmed.gov) using the terms ‘[disease name]’ and ‘reproduction
number’ in the ‘all fields’ search box in September 2011. The
search was then repeated replacing ‘reproduction number’ with
‘reproduction ratio’, ‘reproduction rate’, ‘reproductive number’,
‘reproductive ratio’ and ‘reproductive rate.’ That search pattern
was reiterated with ‘[Genus species]’ or ‘[diseases synonym]’
replacing ‘[disease name],’ if applicable. This procedure was also
performed in ISI-Web of Knowledge (http://isiwebofknowledge.
com) in the ‘title/keywords/abstract’ field. These searches often
produced few or no results and the entire search process would
be conducted again using Google Scholar (http://scholar.google.
co.uk). Data regarding R0 values and the reservoir species when
relevant were abstracted from references obtained, and if multiple
R0 estimates were reported among sources fora single disease, the
rangeofestimateswasrecorded.TherangeforallR0estimateswas
assumed to start from 0.
(iii) Thumbnail maps
To visualize the approximate endemic regions of a disease,
simple maps were constructed from the distribution data pro-
vided by GIDEON. A list of 275 global countries and
territories were coded as 1 for endemic and 0 for non-endemic
for each listed disease. The database was then imported into
ArcGIS 10 (ESRI 2010) and displayed as global maps at the
national level.
(iv) Occurrence data availability and quality
To determine the relative amount of information available for the
various infectious diseases, a search was done using only the dis-
ease name as the text term in PubMed on 4 November 2011 and
using the species name in GenBank on 1 March 2012 (for selected
diseases). Data on the number of feeds for each disease from the
start of data collection were received from HealthMap and
ProMED on 23 November 2011 and from BioCaster on 24 Febru-
ary 2012. Because only data from manual searches of PubMed
has, to our knowledge, been used in mapping, we base our ana-
lyses on PubMed figures only, but provide the potential data
from the other sources in the electronic supplementary material.
These may improve the prospects for mapping of many of the
diseases once the utility of these information sources has been
confirmed by experiment.
(c) Decision rules devised to categorize mapping
options
Decision rules were created for disease mapping options, shown
schematically in figure 2. The Option 1, do not map, classification
was used for those conditions which are known to occur
diseases of
clinical
significance
N=355
spatial variation
in occurrence
Option 1:
do not map
n = 181
Option 2: map
observed
occurrence
n = 64
Option 3: map
maximum potential
range
n = 32
Option 4: niche
mapping
(e.g. BRT)
n = 68
Option 5: model
based geostatistics
(MBG)
n = 10
high volume
reservoir data
geographic limits of disease extent
N
NYY Y N
N
N
N
understand ecology
high volume
disease data occurrence only prevalence
YY
Figure 2. A schematic of the disease classification process. The classification system results in diseases being categorized into one of five options: (1) do not map; (2)
map observed occurrence; (3) map maximum potential range of reservoir or vectors; (4) niche/occurrence mapping with BRT and (5) MGB-based endemicity maps.
r
s
t
b
.
r
o
y
a
l
s
o
c
i
e
t
y
p
u
b
l
i
s
h
i
n
g
.
o
r
g
P
h
i
l
T
r
a
n
s
R
S
o
c
B
3
6
8
:
2
0
1
2
0
2
5
0
4worldwide, and hence do not show sustained spatial variation in
occurrence. The diseases within this category range from sexu-
ally transmitted diseases such as Chlamydia, viral agents such
as Epstein–Barr Virus or rhinoviruses causing the common
cold and endogenous diseases (infections caused by previously
dormant or inapparent pathogens, often from the typical com-
mensal microbial flora of humans—such as urinary tract
infections caused by Escherichia coli or brain abscesses by Staphy-
lococcus aureus). The incidence of these diseases may show
enormous spatial variation. These differences are linked often
to variation in human or human-related factors, however, and
are best mapped using techniques associated with the cartogra-
phy of non-infectious disease [88]. More traditional surveillance
within this cosmopolitan distribution, therefore, may have a
public health rationale and this is explored on a case by case
basis in the electronic supplementary material. For most of
these conditions, it would be useful to apply a simple mask
of human population density to give a more realistic picture of
where the disease is truly observed globally. Option 2, map the
observed occurrence, would apply to diseases that have few data
available and limited information regarding the disease ecology.
A cut-off of fewer than 25 PubMed hits per endemic country was
applied to designate a paucity of data for any operationally sig-
nificant disease. For example, Mayaro virus has 90 search results
on PubMed for 11 potentially endemic countries and, therefore,
only about eight results per country. There has also not been a
definitive reservoir host identified for Mayaro, which would be
needed for the following option. Option 3, map the maximum
potential range, is appropriate for a disease that also has fewer
than 25 PubMed results per country, but information is available
regarding reservoir or vector species that would place bound-
aries on the potential disease distribution, as is the case with
African tick bite fever with its known vector distribution. Map-
ping of the disease using ecological niche modelling, Option 4,
would implement BRT technology on observed occurrence data.
Adequate information regarding occurrence of disease (greater
than 25 PubMed hits per country) is needed to use this strategy.
This information would be usefully supplemented with infor-
mation on where the disease is not found, obtained through
systematic searches or derived by expert opinion maps. If the
authors were aware of systematic searches of occurrence data
that were significantly richer than the PubMed hits, these were
documented and the mapping option re-evaluated accordingly.
Option 5, the implementation of MBG to mapping, is reserved for
diseases that have more than 25 results per country of systemati-
cally recorded prevalence data. This strategy uses MBG for the
creation of complete endemicity maps with detailed uncertainty
metrics. The mapping option to be used is dependent on the
amount and nature of the disease data available, implying that
diseases currently classified for one option would be eligible
for a higher grade in the future as further data become available.
(d) Scoring the quality of existing mapping of the
geographical distribution of disease
It was also of critical interest to obtain information regarding
the extent to which the diseases had been previously mapped.
A search was again conducted in PubMed using the text terms
‘[disease name/synonym]’ and ‘map’ as well as ‘[disease name/
synonym]’ and ‘epidemiology,’ selecting for reviews in October
2011. If an excess of results were returned (more than 1000), this
was further narrowed using the search terms ‘distribution’ or
‘global.’ For diseases transmitted by a specific vector, the search
was repeated using the text terms ‘[vector species name]’ and
‘map.’ The same process was repeated for prominent reservoir
species. The search was also performed using ISI-Web of Knowl-
edge. Irrelevant references were removed from the search output,
and all references regarding the spatial temporal distribution of a
disease, vector or reservoir were checked to determine the par-
ameter mapped (for example, occurrence, prevalence, incidence,
or risk) and in what geographical region.
In order to allow for both relative and quantitative assess-
ment of each map, we devised a metascore, which evaluated
three criteria: data quality, geographical scope and the mapping
technique used.
Data quality (out of nine) was scored in three ways. (i) Con-
temporariness, where three points were awarded if data less than
10 years old was used, two points for the use of data greater than
or equal to 10 years to less than 20 years old, and one point for
data greater than 20 years old. If no age could be identified, no
points were given. For papers reporting a range of dates, the
score was based on the most recent, with the exception of
databases that provide country-specific estimates that were sur-
veyed across different time periods. In that case, an additional
half point (2.5) was given. (ii) Diagnostic accuracy, where three
points were awarded for the use of data diagnosed by genotype
or PCR, or in the case of vector maps, where advanced modelling
techniques had been used on a large number of occurrence
points. Two points were given to those studies that had used hos-
pital or national health surveys or confirmed case reports; an
additional half a point was gained if serological or immunologi-
cal data had been used. Vectors maps received two points if
simple interpolation techniques had been used on occurrence
data. One point was awarded if cited literature had been used.
One point was also given for unpublished health organization
data collected as part of routine health management information
systems (HMIS) or presumptive diagnosis, with a half point
given to non-specific numerical data. The use of expert opinion
in drawing vector maps was awarded one point. If the data
came from an unknown source, or was not listed in the article,
no points were awarded. (iii) Geo-positional accuracy, where
three points were awarded for the use of data coupled with
GPS coordinates, two points if survey coordinates could be
derived from supporting maps, or data was provided to admin-
istrative level 1; an additional half a point was earned if
administrative level 2 was used, or towns and villages were
specified. One point was gained if approximate coordinates of
unknown provenance or country level data was present. Expert
opinion ranges obtained from cited literature received half a
point. If no geo-positional data was associated with the map,
no points were awarded.
The geographical scope was scored out of 100. The GIDEON
endemic country lists for each disease were converted into
national populations at risk using the UN population data
from 2010 [89]. Each map was assessed for how many countries
were included (rounded up to the national level, to match the
resolution of GIDEON), and population covered was calculated
and expressed as a percentage (out of 100%) of the GIDEON
endemic total.
The mapping technique used (mapping option used/theor-
etically best mapping option) was calculated using the criteria
outlined above, each map was evaluated for the mapping
option used (for example, if BRT modelling techniques had
been used, the map was to Option 4 standard), and was related
to the potential mapping option that could be used, based upon
the amount and quality of data present for that disease. For
instance, if a map of Lassa fever (which is an Option 4 disease
owing to there being more than 25 PubMed hits per country)
only uses occurrence points (Option 2 standard), a score of 2/4
would be achieved.
The metascore was then calculated as the product of these
figures ([Quality]/9  [Scope]  [Option Used]/[Option Poten-
tial]) resulting in a maximum of 100. Scores of greater than or
equal to 75 per cent were deemed to have evaluated the global
distribution of the specific disease to a satisfactory standard.
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53. Results
The electronic supplementary material provides full details
of all the epidemiological and mapping evidence collated
and scored and the decision rules applied. The electronic sup-
plementary material includes a summary page on each of the
355 diseases with details of the natural history, transmission,
quantity of data available, quality of data from previously
published maps and recommendations for future mapping
endeavours. The information included on natural history
was the ICD-10 code, transmission classification (table 1),
type of pathogen (agent), taxonomic details, mode of trans-
mission, reservoir species (host organism that is a source of
infection or potential reinfection of humans) and incubation
period.
The epidemiological characteristics highlighted include
the vaccine availability, and estimates of the basic reproduc-
tion number (R0) in human and reservoir populations,
where applicable. A number of diseases (126) were con-
sidered to have an R0 value of less than 1 because they are
primarily zoonotic diseases. Citations were provided to sup-
port that transmission occurs mainly in animals. The R0
estimates ranged from point source outbreaks of diarrhoeal
diseases or less than 1 for zoonoses to 100 for P. vivax malaria
and Ross River virus and 1000 for P. falciparum malaria. Esti-
mates were not obtained for many of the reservoir species,
but for those that were found, the range was from 1.06 for
Old World mucocutaneous leishmaniasis in dogs to 28 for
West Nile fever virus in birds.
Occurrence details included information on the number
of PubMed and GenBank hits, relevant reports from Health-
Map, ProMED and BioCaster feeds, and the approximate
number of endemic countries. A table of previously pub-
lished maps was included incorporating information on
whether the map is of the disease, vector or host reservoir;
geographical scope; data quality score; mapping option
used; metascore; citation.
The option for future mapping (figure 2) was determined
using the PubMed hits returned and the number of endemic
countries per diseases (see the electronic supplementary
material). A total of 181/355 were classified as Option 1
(do not map); 64 were classified as Option 2 (map observed
occurrence); 32 were classified as Option 3 (map maximum
potential range); 68 were classified as Option 4 (map using
BRT) and 10 were classified as Option 5 (map using MBG).
There are trends within the diseases that have a strong
rationale for mapping. Unsurprisingly, endogenous diseases
exhibit little sustained spatial variation in occurrence,
whereas those transmission categories that are inherently
linked to some feature of the environment, or other factor
that varies on a global scale, such as vector-borne disease,
water contact and soil contact tend to show greater variation.
The remaining transmission types have just under half of
the diseases showing differing global patterns of distribution.
Similar trends are also apparent when we consider the occur-
rence of agents of disease—nearly two-thirds of diseases
caused by parasites show tendency to vary over a spatial
scale, as do 61 per cent of all viruses; on the other hand,
there is evidence for spatially variable distributions in only
28 per cent of bacteria. Clearly, these sets of results are
inherently linked; of the 61 viral diseases that would benefit
from having mapped distributions, 41 are vector-borne and
a further eight are soil contact; of those bacterial species
that are not endemic worldwide, about two-thirds are
vector-borne. Such a trend is not so apparent when consider-
ing parasitic diseases and their routes of transmission (many
are food/water-borne). This could be due to their require-
ments for external development, and thus potentially
environmentally determined life cycles.
Of the 174 diseases with strong rationale for mapping,
only seven had maps that scored higher or equal to 75 per
cent on the metascore. These were coltiviruses (Old World),
dengue, Lassa fever, Mayaro, monkey pox, P. falciparum
and P. vivax; all vector-borne diseases. Figure 3a shows
radial plots of all the 174 diseases with a rationale for map-
ping, as well as separate plots by agent (figure 3b–e). The
white line represents the highest scoring metascore for each
disease; the black space above each individual line equates
to the information deficit present.
4. Discussion
We have collated a significant amount of information on 355
diseases of clinical importance and have made evidence-
based suggestions on the appropriate cartographic approaches
to use in mapping each disease. These have been summarized
in the results and are elaborated for each disease in the elec-
tronic supplementary material. In the following sections, we
review some of the common omissions in existing maps and
look to novel data sources, new techniques and information
technology developments that may change the future land-
scape of infectious disease mapping.
This review has provided the opportunity to make some
preliminary observations on some of the common omissions
in infectious disease mapping that might be considered when
embarking on new cartographies. They are as follows.
Table 1. The number of clinically important infectious diseases and the subset
of those with a rationale for mapping by transmission category (see §2).
classiﬁcation
clinically
signiﬁcant
diseases
(n 5 355)
diseases with
rationale for
mapping
(n 5 174)
animal contact 20 9
blood/body
ﬂuid contact
14 5
direct contact 23 7
endogenous
a 35 0
food/water-
borne
82 36
respiratory 39 9
sexual contact 11 2
soil contact 21 14
unknown 11 4
vector-borne 88 80
water contact 11 8
aEndogenous infections are those caused by previously inapparent or dormant
pathogens arising from the typical commensal microbial flora of humans.
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6(a) Other relevant maps
The most consistent omission is the lack of additional
information that can provide significant epidemiological
insight—often referred to as ‘expert opinion’. These definitive
extent data can be an ad hoc collection for each disease that
may include information on biological and biogeographic
limits (often as range maps), as well as, further distribution
or occurrence data on intermediate and reservoir hosts.
There are several occurrence mapping methods that can use
this information, such as weighted forms of BRT that have
been trialled extensively with respect to the anophelines
[72–75] (figure 1). They do this by overcoming the biogeo-
graphic and taxonomic ignorance of all occurrence mapping
techniques that assume the globally realized niche approxi-
mates the fundamental niche. The careful use of definitive
extent data would substantially reduce the degree to which
inferences are required.
(b) Formalizing expert opinion
Further investigation is also advised on using the Cooke
method to help determine the importance ascribed to the
expert opinion [90,91]. Essentially these methods allow a
simple way to gauge the accuracy of an expert source by test-
ing their knowledge on a set of subject related questions to
which the answers are well known. For a cartographic pro-
blem set, this could be very easily formalized by rating
answers for a related disease we know the distribution of
extremely well. It may be possible to link this with BRT
and formalize the weights that are ascribed to other relevant
epidemiological information.
(c) Human population distribution
There is a systematic deficit in the use of human population
distribution maps [92,93], both as a mapping covariate and
for determining the population at risk of infection or the
reservoir of infection. Some effort may also be invested in
incorporating the latest human population surfaces into the
information suite. The diseases for which human population
distribution may help refine risk assessments, including both
those with a rationale for mapping and those ubiquitous
clinically important diseases for which the recommendation
was not to map, have been highlighted (see the electronic
supplementary material).
(d) Refining of environmental covariates
Most cartographic applications use environmental covariates
crudely without any adjustment to the epidemiology of the
diseases concerned. Where detailed information and exper-
iments on the environmental responses of a disease have
been conducted it has proved valuable to combine this with
the covariate. An example would be the way that temperature
data have been used not only to map the environmental
limits of P. falciparum and P. vivax globally [94], but have
also been transformed into indexes of transmission suit-
ability. These indexes were more strongly selected for by
the model than untransformed covariates in endemicity map-
ping. The diseases to which such advances may be relevant
are indicated (see the electronic supplementary material).
(e) Public health interventions
It is still rare for geographically specific intelligence on public
health interventions to be used in the mapping of diseases.
(a)( b)
(d)( e)
(c)
Figure 3. Radial plots for all diseases with a rationale for mapping, ordered clockwise, by metascore (white line). A white line from the centre to the edge of
the circle would show a perfect metascore. (a) Reflects all diseases (n ¼ 174 of 355), (b) viral diseases (n ¼ 62 of 101), (c) parasitic diseases (n ¼ 61 of 96),
(d) bacterial diseases (n ¼ 36 of 128), and (e) comprises fungal (n ¼ 9 of 17), protoctistan (n ¼ 2 of 2) and diseases of unknown pathogen (n ¼ 4 of 10).
Note that there was one algal disease, which did not have a rationale for mapping and is not shown in this diagram.
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7Such information could be used in the same way as other
‘expert opinion’ data sources by BRT. Where human interven-
tions have significantly affected the distribution of a disease,
for example vaccine coverage in a population [95–97], this
has been identified. We have sought to identify those diseases
for which this information may be relevant but have not
searched systematically for the availability of relevant
public health information.
There are many potential novel data sources that may be
used for global infectious disease mapping. The resources
described below have never been used systematically to
address the paucity in occurrence data across the range of infec-
tious diseases reviewed. Substantial progress will be made
from exploiting the geospatial information in the formal litera-
ture (e.g. PubMed, www.ncbi.nlm.nih.gov/pubmed) and in
genetic and protein sequence databases (e.g. GenBank, www.
ncbi.nlm.nih.gov/genbank). The potential information avail-
able has been identified for each disease in the electronic
supplementary material and is further summarized in table 2.
Significant prospects for the rapid acquisition of occur-
rence data are also clearly possible from online outbreak
alert resources (i.e. HealthMap/ProMED [24,25], BioCaster
[26,27] and Argus [28,29] records). The potential information
available has been identified for each disease in the electronic
supplementary material and is further summarized in table 3
for those systems where data can be freely shared.
Finally, there is a revolution occurring in both the volume
and public availability of data about the health and wellbeing
of individualsandpopulationsthroughvarious formsof social
media [103]; most notably Twitter (twitter.com). This is an
online social media site that allows users to post ‘Tweets’;
messages less than or equal to 140 characters which
are freely available to all. It took 3 years to reach the first
billion Tweets, but by March 2011, it took only a week to
reach one billion posts and 140 million Tweets are now
posted daily with an increasing numberof them automatically
geo-positioned.This wealth of accurately geo-positioned infor-
mation has already begun to be harvested for public health
purposes. Twitter feeds surrounding the 2009 H1N1 flu out-
break were analysed and found to predict outbreaks one to
two weeks in advance of traditional surveillance [104,105].
Tweets can also be analysed to identify a broader range
of health-related terms such as symptoms, syndromes and
treatments to illuminate geographical patterns in syndrome
surveillance [106].
Our optimism about the future use of social media is
tempered by the realization that the main contemporary
issue in disease mapping, of dealing with the lack of relevant
data, will subside, and that our new challenges will be infor-
matics, developing systems and processes to take on the
big data challenges of the future. This is discussed in the
following section.
Table 2. The cartographically relevant holdings of the National Center for Biotechnology Information PubMed and GenBank systems. The searches were
conducted on 4 November 2011 and 1 March 2012, respectively.
system PubMed GenBank
start year 1946 [98] 1982 [99]
frequency of updates daily [98] Daily [100]
number of species catalogued .250000 [100] .250 000 [100]
approximate number of entries 21 million [101] 340 million [100]
number of clinically relevant diseases for which data are available 168 155
occurrence point sources for mapping 526564 672 327
Table 3. Geo-positioned occurrence data archived by the HealthMap and BioCaster online disease outbreak reporting systems. HealthMap uses automated text
processing to classify and position alerts that are then conﬁrmed by a human analyst [25]. BioCaster has automated text processing to classify and position
alerts processed through a multilingual ontology [26]. The totals were assembled using data provided for HealthMap on 23 November 2011 and BioCaster on 24
February 2012.
system HealthMap BioCaster
start year 2006 2006
approximate posts per day 300 [24] 100 [29]
number of languages 10 (J. S. Brownstein 2012, personal communication) 11 [102]
number of diseases tagged 245 (J. S. Brownstein 2011, personal communication) 230 (N. Collier 2012, personal communication)
number of clinically relevant
diseases for which data are
available
84 of 245 99 of 230 (N. Collier 2012, personal
communication)
total occurrence points 337 105 (J. S. Brownstein 2011, personal
communication)
189 361 (N. Collier 2012, personal
communication)
occurrence point sources for mapping 66 284 (J. S. Brownstein 2011, personal
communication)
140 038 (N. Collier 2012, personal
communication)
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8There are also many novel techniques that may be used to
improve the prospects of global infectious disease mapping,
notably automation through machine learning and harnes-
sing the cognitive surplus. In the defined schema (figure 2),
it is more logistically and technically difficult (and thus
expensive) to map diseases from Option 1 (do not map)
through to Option 5 (map endemicity with MBG). It is also
more expensive to deal with conditions for which data retrie-
val is a significant logistical obstacle. This will be directly
proportional to the number of PubMed and other (see earlier)
data source hits identified.
The HealthMap and BioCaster systems have pioneered
machine learning algorithms that automatically classify rel-
evant reports, identify the infectious disease of interest and
determine the geographical location of the outbreak. Scaling
these to cope with this potential data deluge is a non-trivial
but largelytechnical problem.Ideally, theresultsofthis process
shouldbeauditedandverifiedbysubjectmatterexpertsbutthis
is non-scalable, time consuming and prohibitively expensive.
As an alternative, developments in social computing have
led to increased interest in using large numbers of non-experts
as a cheaper and scalable method for data filtering: the
so-called crowdsourcing or distributed cognition [107,108].
Currentlyestablished waysto crowdsource exist (i)framing fil-
tering tasks as fun online games, incentivizing users to filter
data for free [109] and (ii) posting the task online and seeking
non-experts using a pay-per-example setting as pioneered by
the Amazon Mechanical Turk system [110,111]. The central
idea isthat, ifquestions canbe structured ina simpleand intui-
tive way, and presented to a large number of individuals, the
central tendency of responses is likely to provide an accurate
answer. Crowdsourcing is particularly appealing in the con-
text of filtering social media disease reports because of the
non-expert nature of key components of the task, such as
geo-positioning. Crowdsourcing is not, of course, a panacea
for data filtering. The reliability of contributors must be
quantitatively assessed and iteratively adjusted for, again
with reference to a gold-standard reference set of externally
validated results.
In conclusion, this systematic review has shown that we
have an astonishingly poor knowledge of the global distri-
bution of the vast majority of infectious diseases of clinical
importance. Less than 5 per cent of clinically important infec-
tious diseases have been mapped reliably. This presents clear
obstacles to advances in determining the global burden of
these conditions, our ability to differentiate outbreaks of con-
cern in international biosurveillance, and our ability to
understand the geographical determinants of disease emer-
gence, past, present and future. We have shown that
contemporary solutions exist to enable us to use new data
and new technology to rapidly improve the cartography of
a wide range of clinically important pathogens. Few concep-
tual barriers exist to making rapid progress and to ‘seeing
further’ into the relatively unknown landscape of infectious
disease mapping.
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gramme of the Science & Technology Directorate, Department of
Homeland Security, and the Fogarty International Center, National
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or preparation of the manuscript. Thanks are extended to Dr Kevin
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